| Literature DB >> 36194621 |
Huiling Tan1,2, Xin Wang1,2, Kaiyou Ye3, Jianmin Lin4, E Song5, Lihua Gong1.
Abstract
BACKGROUND: To investigate the prevalence and risk factors of diabetic retinopathy (DR) in a Chinese population with type 2 diabetes mellitus (T2DM) in a suburb (Qingpu) of Shanghai, China.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36194621 PMCID: PMC9531829 DOI: 10.1371/journal.pone.0275617
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
The International Clinical Diabetic Retinopathy Severity Scale.
| Diabetic Retinopathy Severity Level | Findings Observable upon Ophthalmoscopy |
|---|---|
| No diabetic retinopathy (NDR) | No abnormalities |
| Mild non-proliferative DR (Mild NPDR) | Microaneurysms only |
| Moderate NPDR | More than mild NPDR but less than severe NPDR |
| Severe NPDR | No signs of proliferative retinopathy (PDR) and any of the 4:2:1 rule: >20 intraretinal hemorrhages in each of 4 quadrants; definite venous beading in 2 quadrants; prominent intraretinal microvascular abnormalities in 1 quadrant. |
| Proliferative DR (PDR) | Neovascularization or vitreous/preretinal hemorrhage |
Characteristics of study subjects by the presence of DR.
| Variables | All | NDR | Mild NPDR | Moderate NPDR | Severe NPDR | PDR |
|
|---|---|---|---|---|---|---|---|
|
| 2875 | 72 | 173 | 41 | 11 | 72 | 0.209 |
|
| 63.84±7.53 | 63.94±7.49 | 61.41±8.40 | 63.38±7.65 | 62.26±8.00 | 64.85±5.45 |
|
|
| 161.56±7.60 | 161.59±7.57 | 161.94±7.73 | 160.86±8.04 | 162.41±7.83 | 160.74±6.52 | 0.185 |
|
| 64.26±11.87 | 64.40±12.02 | 62.85±10.23 | 63.18±10.77 | 62.80±8.76 | 62.48±9.36 |
|
|
| 24.61±4.45 | 24.66±4.55 | 23.92±3.20 | 24.37±3.52 | 23.8±2.94 | 24.16±3.25 |
|
|
| 6.40 (2.70–12.00) | 6.00 (2.50–11.18) | 8.00 (3.90–14.00) | 9.00 (4.83–15.00) | 8.00 (3.13–15.75) | 13.00 (8.00–18.00) |
|
|
| 8.89±2.64 | 8.71±2.48 | 9.76±2.89 | 10.48±3.58 | 10.97±3.49 | 10.79±3.30 |
|
|
| 7.30±1.47 | 7.20±1.42 | 7.88±1.51 | 8.14±1.73 | 8.34±1.74 | 8.37±1.76 |
|
|
| 1.37 (0.91–2.09) | 1.39 (0.92–2.10) | 1.27 (0.87–1.93) | 1.26 (0.85–1.93) | 1.28 (0.77–2.15) | 1.44 (0.81–2.15) | 0.101 |
|
| 5.35±1.13 | 5.34±1.12 | 5.11±1.09 | 5.44±1.31 | 5.67±1.17 | 5.28±1.13 |
|
|
| 4.41±2.66 | 4.39±2.65 | 4.46±2.46 | 4.72±2.78 | 4.78±2.99 | 4.44±2.31 | 0.084 |
|
| 1.33±0.31 | 1.33±0.31 | 1.29±0.30 | 1.38±0.34 | 1.38±0.33 | 1.44±0.38 |
|
|
| 3.22±0.95 | 3.21±0.94 | 3.08±0.98 | 3.30±1.03 | 3.35±0.95 | 3.08±1.01 | 0.081 |
|
| 5.99±1.66 | 5.95±1.60 | 6.04±1.65 | 6.27±2.18 | 6.61±2.40 | 6.25±1.96 |
|
|
| 61.69±20.64 | 61.57±19.35 | 59.59±16.55 | 63.29±33.45 | 64.76±28.15 | 64.52±27.52 | 0.352 |
|
| 18.00 (7.00–9284.00) | 1466.50 (7.00–9666.75) | 17.00 (8.00–8065.00) | 8.00 (5.00–4516.25) | 7.00 (4.00–17.25) | 7.00 (4.00–4309.00) |
|
|
| 12.30 (5.23–33.20) | 12.10 (5.20–31.80) | 10.00 (4.80–33.30) | 15.00 (5.78–73.98) | 23.90 (8.90–66.63) | 11.20 (4.20–173.00) |
|
|
| 12.10 (5.90–33.18) | 11.70 (5.70–30.78) | 10.70 (5.40–33.30) | 19.15 (7.48–83.83) | 33.15 (9.38–93.75) | 20.30 (9.30–177.60) |
|
NDR, no diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; BMI, body mass index; DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BUN, blood urea nitrogen; Scr, serum creatinine; Ucr, urinary creatinine; U-Alb, urinary albumin; UACR, urine albumin-to-creatinine ratio. Results are expressed as mean ± SD or medians (IQR); p values of DR group were compared by: a = analysis of variance, b = Kruskal–Wallis H test.
Age-and gender-specific prevalence (95% CI) of DR in study subjects.
| N | Any DR | Mild NPDR | Moderate NPDR | Severe NPDR | PDR | Bilateral DR | |
|---|---|---|---|---|---|---|---|
|
| 6380 | 10.1(9.4–10.8) | 2.1(1.8–2.5) | 6.3(5.7–6.9) | 1.3(1.0–1.5) | 0.4(0.3–0.6) | 6.5(5.9–7.1) |
|
| |||||||
| Male | 2875 | 10.3(9.2–11.4) | 2.5(1.9–3.1) | 6(5.1–6.9) | 1.4(1.0–1.8) | 0.4(0.2–0.6) | 6.7(5.8–7.6) |
| Female | 3505 | 9.9(8.9–10.9) | 1.8(1.4–2.2) | 6.5(5.7–7.4) | 1.1(0.8–1.5) | 0.5(0.3–0.7) | 6.3(5.5–7.1) |
| 0.570 | 0.051 | 0.399 | 0.263 | 0.651 | 0.547 | ||
|
| |||||||
| ≤39 | 22 | 9.1(0–22.2) | 4.5(0.0–15.0) | 4.5(0.0–15.0) | 0.0(0.0–0.0) | 0.0(0.0–0.0) | 9.1(0.0–22.7) |
| 40–49 | 198 | 16.7(11.7–21.7) | 4.5(1.6–7.4) | 9.1(5.3–13.1) | 3.0(0.6–5.6) | 0.0(0.0–0.0) | 13.1(8.6–17.9) |
| 50–59 | 1486 | 11.3(9.7–12.9) | 2.8(2.0–3.7) | 6.9(5.6–8.3) | 1.3(0.8–1.9) | 0.3(0.0–0.5) | 7.9(6.6–9.3) |
| 60–69 | 3216 | 10.0(8.9–11) | 2.0(1.5–2.5) | 6.0(5.2–6.9) | 1.4(1.0–1.8) | 0.6(0.3–0.9) | 6.4(5.6–7.2) |
| 70–79 | 1380 | 8.3(7–9.8) | 1.3(0.8–1.9) | 5.9(4.8–7.1) | 0.7(0.3–1.2) | 0.4(0.1–0.7) | 4.2(3.2–5.3) |
| ≥80 | 78 | 9(3.1–16.2) | 1.3(0.0–4.3) | 6.4(1.5–12.3) | 1.3(0.0–4.6) | 0.0(0.0–0.0) | 2.6(0.0–6.8) |
|
|
| 0.473 | 0.118 | 0.601 |
|
Risk factors of DR in the study.
| Variables | Age-gender adjusted OR (95% CI) |
|
|---|---|---|
|
| 0.823 (0.737–0.919) |
|
|
| 0.873 (0.746–1.023) | 0.092 |
|
| 0.999 (0.956–1.044) | 0.967 |
|
| 1.057 (1.042–1.072) |
|
|
| 1.063 (1.020–1.108) |
|
|
| 1.269 (1.176–1.369) |
|
|
| 0.911 (0.842–0.985) |
|
|
| 1.225 (0.926–1.621) | 0.155 |
|
| 1.059 (1.010–1.111) |
|
|
| 1.000 (1.000–1.000) |
|
|
| 1.001 (1.001–1.002) |
|
|
| 1.000 (1.000–1.000) | 0.976 |
Fig 1The results of principal component analysis (PCA).
(A) The two-dimensional PCA results are based on the first and second principal components. (B) Contributions of variables to the first principal component. Abbreviations: DR, diabetic retinopathy; NDR, no diabetic retinopathy; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; DM, diabetes mellitus; BUN, blood urea nitrogen; U-Alb, urinary albumin.
Fig 2Spearman correlation analysis results about the correlation between FPG (A)/ HbA1c (B) and the intensity of fundus degeneration.
R, correlation value by Spearman correlation analysis; P, significance level in Spearman correlation analysis. Abbreviations: DR, diabetic retinopathy; DR severity: 1(NDR, no diabetic retinopathy), 2(Mild NPDR, mild non-proliferative diabetic retinopathy), 3(Moderate NPDR), 4(Severe NPDR), 5(PDR, proliferative diabetic retinopathy); FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c.